Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease-Reference-Cited by-同舟云学术

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Published:2017-09-05 Issue:10 Volume:136 Page:969-972
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Kappel Ben A.¹,Lehrke Michael¹,Schütt Katharina¹,Artati Anna¹,Adamski Jerzy¹,Lebherz Corinna¹,Marx Nikolaus¹

Affiliation:

1. From Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany ...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.117.029166

Reference5 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Evolving Concepts of Myocardial Energy Metabolism

3. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

4. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

5. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitors;Frontiers in Cellular and Infection Microbiology;2024-09-10

2. Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography;Clinical Kidney Journal;2024-08-14

3. Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?;Journal of Veterinary Pharmacology and Therapeutics;2024-07-13

4. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review;International Journal of Molecular Sciences;2024-06-27

5. Adverse plasma branched‐chain amino acid profile mirrors fatty muscle degeneration in diabetic heart failure patients;ESC Heart Failure;2024-05-29